AD8.5 Other Safety Findings
AD8.5.1 ADE Incidence Tables
BODY SYSTEM / ADVERSE
EXPERIENCE |
Bupropion
sustained-release Dosing Group |
||
|
150
mg/d (N=147) |
300
mg/d (N=147) |
Placebo (N=150) |
Vomiting |
2.0% |
3.4% |
2.0% |
Toothache/Tooth Abscess |
0.7% |
1.4% |
1.3% |
Flatulence |
2.0% |
2.7% |
2.7% |
Anorexia |
3.4% |
4.8% |
2.7% |
Dyspepsia |
4.8% |
2.7% |
5.3% |
Body (General) |
|||
Headache |
23.1% |
25.9% |
18.0% |
Chest Pain |
1.4% |
3.4% |
0.7% |
Asthenia |
2.7% |
1.4% |
1.3% |
Back Pain |
2.0% |
2.7% |
2.7% |
Fever |
0.7% |
0% |
0.7% |
Neck Pain |
1.4% |
0.7% |
0.7% |
Accidental Injury |
3.4% |
0.7% |
1.3% |
Abdominal Pain |
4.1% |
3.4% |
0.7% |
Respiratory System Disorders |
|||
Pharyngitis |
1.4% |
2.7% |
2.0% |
Rhinitis |
10.2% |
4.1% |
11.3% |
Sinusitis |
2.7% |
3.4% |
2.7% |
Respiratory Complaints |
0% |
0.7% |
0% |
Laryngitis |
0.7% |
1.4& |
0.7% |
Skin and Appendages Disorders |
|||
Sweating |
2.0% |
4.1% |
2.0% |
Rash |
1.4% |
2.0% |
2.0% |
Pruritus |
2.0% |
0% |
1.3% |
Urticaria |
1.4% |
1.4% |
0% |
Acne |
1.4% |
2.7% |
0% |
Back a Page
Next Page
Back to Wellbutrin SRŪ NDA Index Page
Back to Main
Index